Adults With Schizophrenia or Bipolar Disorder Can Now Use Igalmi Film at Home for Acute Agitation Episodes
Adults with schizophrenia, schizoaffective disorder or bipolar I or II disorder can now be prescribed a dissolving film to use at home when acute agitation starts, after the U.S. Food and Drug Administration approved an expanded use of Igalmi, Psychiatric Times reported Nov. 16. Until now, Igalmi (dexmedetomidine) could be used only under the supervision of a health care provider. Its maker, Teva Pharmaceuticals, says the change makes Igalmi the first FDA-approved treatment for these agitation episodes that patients can use at home. For families, that could change what happens during a hard night. Agitation episodes linked to these conditions can escalate to an emergency room visit, a crisis call or a stressful scramble by relatives who are trying to help. A home option gives some patients and caregivers another step to discuss with a psychiatrist before a crisis begins. There is an important limit. The at-home trial behind the approval was designed to measure safety and tolerability, not whether the drug works as well at home as in a clinic. Evidence that the drug calms agitation comes from the earlier supervised trials. A Familiar Drug in a New Setting Igalmi is a thin film placed under the tongue or inside the cheek, where it dissolves. Its active ingredient, dexmedetomidine, is a sedative long used intravenously in intensive care units. The film version was first approved in April 2022 for supervised use in adults. That first approval rested on two placebo-controlled phase 3 trials, SERENITY I in schizophrenia and SERENITY II in bipolar disorder. In both, patients given the film showed significant improvement in agitation two hours after the first dose, as Psychiatric Times reported when the at-home application was filed. The original developer, BioXcel Therapeutics, submitted the application to expand use outside medical settings on Jan. 14, 2026. The FDA accepted it for review by April. Teva acquired global rights to the drug on Oct. 27, weeks before the decision. Chris Fox, Teva's executive vice president for U.S. commercial, said the company is now positioned "with the first FDA-approved, at-home treatment for agitation associated with these conditions," in the company's approval announcement . Teva said it will announce at-home commercialization plans later, so pricing and pharmacy availability are not yet known. The Home Trial Measured Safety First The approval was supported by the phase 3 SERENITY At-Home trial. It enrolled 102 adults who used the film at home over 12 weeks, treating 1,160 agitation episodes in total, according to Teva. The trial's primary goal was safety and tolerability, and the company says that goal was met. Teva reported no discontinuations due to tolerability among people taking Igalmi in the study. The most common side effects, reported in at least 5% of patients and more often than with placebo, were sleepiness, dry mouth, dizziness and numbness or tingling in the mouth. Exact percentages for the home trial were not included in Teva's announcement. The supervised label already carries cautions that matter more at home. According to a NAMI medication fact sheet , dexmedetomidine can lower blood pressure, and people should not drive or operate machinery for at least eight hours after a dose. In clinics, staff watch vital signs to prevent falls and fainting. At home, that job may fall to the patient or a family member, often someone with no medical training. Patients and Caregivers Most Likely to Feel the Change The approval applies only to adults with the diagnoses named in the label. It does not cover dementia-related agitation, children or other conditions. People who may benefit most are those who have recurring, recognizable agitation episodes and a stable relationship with a prescriber. Caregivers who live with them, often parents or partners, may also feel the effects. A home option could reduce some emergency visits, though no data yet show that it does. Older adults, people with liver problems and those who take other sedating medicines or blood pressure drugs may need extra caution and dose changes. Decisions about who is a good candidate belong to a psychiatrist or other qualified clinician, not to a family member acting alone. Cost and coverage remain open questions. Without commercialization details, households cannot yet know what insurers or Medicaid will pay. Patients can ask their prescriber and insurer once the drug launches for home use. Planning Before the Next Episode Families can use this news to talk with a clinician about a written crisis plan, including whether an at-home option makes sense. That conversation should cover when to use the film, what side effects to watch for, and when to stop relying on home treatment. Some situations still call for emergency help. Fainting, very low blood pressure, extreme drowsiness, threats of harm to self or others, or agitation that does not ease call for 911 or the 988 Suicide and Crisis Lifeline. A home medication does not replace crisis services. People should not change or stop their current psychiatric medicines in response to this approval without speaking with their prescriber. Readers can watch for Teva's launch details and the updated prescribing information. Key Questions Answered What did the FDA approve? Igalmi sublingual film for at-home use in adults with acute agitation linked to schizophrenia, schizoaffective disorder, or bipolar I or II disorder. Was Igalmi already approved? Yes. It was approved in April 2022, but only for use under the supervision of a health care provider. Did the at-home trial prove the drug works at home? No. The trial's main goal was safety and tolerability. Evidence that the drug reduces agitation comes from earlier supervised trials. What are the common side effects? Sleepiness, dry mouth, dizziness, and mouth numbness or tingling. The drug can also lower blood pressure. Who can use it? Only adults with the diagnoses named in the label, with a prescription from a clinician who decides it is appropriate. When will it be available for home use? Teva has not yet announced commercialization plans, pricing, or launch timing. When should families call for emergency help? Fainting, extreme drowsiness, threats of harm, or agitation that worsens or does not ease call 911 or the 988 Lifeline. Published by Medicaldaily.com